CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	SRF::v	Fusion	Diagnostic	Supports	Positive	Myofibroma And Myopericytoma		Antonescu et al., 2017
B	SRF::v	Fusion	Diagnostic	Supports	Positive	Myofibroma And Myopericytoma		Karanian et al., 2020
B	FOXR2	Rearrangement	Diagnostic	Supports	Positive	CNS Neuroblastoma With FOXR2 Activation		Schepke et al., 2023
A	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Datopotamab Deruxtecan Regimen	Sands et al., 2025
A	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Datopotamab Deruxtecan	Ahn et al., 2025
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		Luatti et al., 2017
A	ERBB2	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Zongertinib	Heymach et al., 2025
D	FGFR1	Amplification OR FGFR1 Overexpression	Predictive	Supports	Resistance	Estrogen-receptor Positive Breast Cancer	CDK4/6 Inhibition,Antiestrogen Therapy	Formisano et al., 2019
A	MSI	High	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Ipilimumab/Nivolumab Regimen	Andre et al., 2024
A	MSI	High	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Ipilimumab/Nivolumab Regimen	André et al., 2025
A	ERBB2	L755P OR ERBB2 G776V OR ERBB2 G776delinsVC OR ERBB2 P780_Y781insGSP	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Zongertinib	Heymach et al., 2025
A	ERBB2	A775_G776insYVMA	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Zongertinib	Heymach et al., 2025
B	TMB	High	Predictive	Supports	Sensitivity/Response	Solid Tumors, Advanced	Immune Checkpoint Inhibitor	Samstein et al., 2019
B	TMB	High	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	PD1 Inhibitor,PD-L1 Inhibitor	Ricciuti et al., 2022
B	TMB	High	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Atezolizumab	Gandara et al., 2018
B	BCR::ABL1	Fusion	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		Bennour et al., 2009
B	TMB	High	Predictive	Supports	Sensitivity/Response	Solid Tumor	Pembrolizumab	Cristescu et al., 2018
B	PIK3CA	Mutation OR PTEN Mutation OR PIK3R1 Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Aspirin	Martling et al., 2025
B	TMB	High	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Ipilimumab/Nivolumab Regimen	Hellmann et al., 2018
A	EGFR	S768_D770dup OR EGFR A767_V769dupASV	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	EGFR	H773_V774insH OR EGFR D770_N771insG OR EGFR H773_V774insNPH OR EGFR A763_Y764insFQEA OR EGFR V774_C775insHV OR EGFR H773_V774insPH OR EGFR H773_V774insAH OR EGFR D770_N771insH OR EGFR N771dup	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	EGFR	D770delinsGY OR EGFR D770_N771insY OR EGFR N771_P772insT OR EGFR H773_V774insGNPH OR EGFR A767_S768insTLA OR EGFR S768_V769insLDS OR EGFR V769_D770insCV OR EGFR V769_D770insGA OR EGFR V769_D770insGVASV OR EGFR D770delinsAS	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	EGFR	D770_N771insGT OR EGFR D770_N771insD OR EGFR D770_N771insF OR EGFR D770_N771insGD OR EGFR D770_N771insT OR EGFR N771delinsCH OR EGFR N771delinsGF OR EGFR N771delinsRD OR EGFR N771delinsSQRGH OR EGFR N771_P772insDN	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	EGFR	N771delinsGY OR EGFR P772_H773insYNP OR EGFR N771_P772insRH OR EGFR N771_P772insVDN OR EGFR P772delinsHR OR EGFR P772_H773insDNP OR EGFR P772_H773insPHP OR EGFR P772_H773insQ OR EGFR P772_H773insRNP OR EGFR H773delinsNPY OR EGFR H773delinsPNPY	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	EGFR	H773delinsYNPY OR EGFR H773delinsYPNPY OR EGFR H773_V774insHPH OR EGFR H773_V774insTH OR EGFR C775_R776insNPHVC	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
A	H3-3A	K27M	Predictive	Supports	Sensitivity/Response	Diffuse Midline Glioma, H3 K27M-mutant	Dordaviprone	Arrillaga-Romany et al., 2024
A	EGFR	Exon 20 Insertion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sunvozertinib	Yang et al., 2025
B	TMB	H-bTMB	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Immune Checkpoint Inhibitor	Wang et al., 2019
B	H3-3A	G34W	Diagnostic	Supports	Positive	Bone Giant Cell Tumor		Presneau et al., 2015
B	H3-3A	G34W	Diagnostic	Supports	Positive	Bone Giant Cell Tumor		Cleven et al., 2015
B	TMB	High	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Toripalimab,Chemotherapy	Xu et al., 2024
B	PDGFRA	D842V	Diagnostic	Supports	Negative	Gastrointestinal Stromal Tumor		Lasota et al., 2004
B	DNMT3A	R882	Diagnostic	Supports	Positive	Acute Myeloid Leukemia		Ribeiro et al., 2012
B	KRAS	G12	Diagnostic	Supports	Positive	Acute Leukemia		Andrade et al., 2014
B	NRAS	Q61	Diagnostic	Supports	Positive	Melanoma		Tschandl et al., 2013
D	MAP2K1	P124S	Predictive	Supports	Resistance	Melanoma	Selumetinib	Emery et al., 2009
D	MAP2K1	Q56P	Predictive	Supports	Resistance	Melanoma	Selumetinib	Emery et al., 2009
D	JAK2	V617F	Predictive	Supports	Sensitivity/Response	Polycythemia Vera	Fedratinib	Wernig et al., 2008
B	NRAS	Mutation	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Therkildsen et al., 2014
B	DNMT3A	R882	Diagnostic	Supports	Positive	Acute Myeloid Leukemia		El Ghannam et al., 2014
D	ALK	F1174L	Predictive	Supports	Resistance	Inflammatory Myofibroblastic Tumor	Crizotinib	Sasaki et al., 2010
D	ALK	F1174L	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Sasaki et al., 2010
D	KIT	L576P	Predictive	Supports	Resistance	Melanoma	Imatinib,Nilotinib,Sorafenib	Woodman et al., 2009
B	KRAS	G12/G13	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Pao et al., 2005
D	ALK	F1174L	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Alectinib	Sakamoto et al., 2011
D	ALK	F1174L	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Crizotinib	Heuckmann et al., 2011
D	ARAF	S214C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sorafenib	Imielinski et al., 2014
D	ARAF	S214C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib	Imielinski et al., 2014
D	KIT	L576P	Predictive	Supports	Sensitivity/Response	Melanoma	Dasatinib	Woodman et al., 2009
D	PDGFRA	I843DEL	Predictive	Supports	Sensitivity/Response	Gastrointestinal Stromal Tumor	Crenolanib	Heinrich et al., 2012

Page 25 of 96

Previous Next